Oncotelic Therapeutics (OTLC) Short Interest Ratio & Short Volume

Short interest is the volume of Oncotelic Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 31st, investors have sold 24,900 shares of OTLC short. 0.01% of Oncotelic Therapeutics' shares are currently sold short. Learn More on Oncotelic Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.01% of Oncotelic Therapeutics' floating shares are currently sold short.

Oncotelic Therapeutics saw a decline in short interest during the month of May. As of May 31st, there was short interest totaling 24,900 shares, a decline of 59.5% from the previous total of 61,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.01% of Oncotelic Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oncotelic Therapeutics: XBiotech Inc. (3.98%), PDS Biotechnology Co. (8.57%), Forte Biosciences, Inc. (3.25%), Immunic, Inc. (4.86%), OncoCyte Co. (1.32%), Pyxis Oncology, Inc. (14.70%), ESSA Pharma Inc. (1.83%), Cellectis S.A. (0.42%), Elutia Inc. (0.27%), Skye Bioscience, Inc. (17.41%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks.

Short selling OTLC is an investing strategy that aims to generate trading profit from Oncotelic Therapeutics as its price is falling. OTLC shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Oncotelic Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OTLC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OTLC, twice per month. The most recent reporting period available is May, 31 2025.